Poly(I:C) Potentiates T Cell Immunity to a Dendritic Cell Targeted HIV-Multiepitope Vaccine

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorAPOSTOLICO, Juliana de Souza
dc.contributor.authorLUNARDELLI, Victoria Alves Santos
dc.contributor.authorYAMAMOTO, Marcio Massao
dc.contributor.authorCUNHA-NETO, Edecio
dc.contributor.authorBOSCARDIN, Silvia Beatriz
dc.contributor.authorROSA, Daniela Santoro
dc.date.accessioned2019-05-30T13:19:47Z
dc.date.available2019-05-30T13:19:47Z
dc.date.issued2019
dc.description.abstractCellular immune responses are implicated in resistance to HIV and have been considered for the development of an effective vaccine. Despite their safety profile, subunit vaccines need to be delivered combined with an adjuvant. In the last years, in vivo antigen targeting to dendritic cells (DCs) using chimeric monoclonal antibodies (mAb) against the DC endocytic receptor DEC205/CD205 was shown to support long-term T cell immunity. Here, we evaluated the ability of different adjuvants to modulate specific cellular immune response when eight CD4(+) HIV-derived epitopes (HIVBr8) were targeted to DEC205(+) DCs in vivo. Immunization with two doses of alpha DECHIVBr8 mAb along with poly(I:C) induced Th1 cytokine production and higher frequency of HIV-specific polyfunctional and long-lived T cells than MPL or CpG ODN-assisted immunization. Although each adjuvant elicited responses against the 8 epitopes present in the vaccine, the magnitude of the T cell response was higher in the presence of poly(I:C). Moreover, poly(I:C) up regulated the expression of costimulatory molecules in both cDC1 and cDC2 DCs subsets. In summary, the use of poly(I:C) in a vaccine formulation that targets multiple epitopes to the DEC205 receptor improved the potency and the quality of HIV-specific responses when compared to other vaccine-adjuvant formulations. This study highlights the importance of the rational selection of antigen/adjuvant combination to potentiate the desired immune responses.eng
dc.description.indexMEDLINEeng
dc.description.sponsorshipSao Paulo Research Foundation (FAPESP) [2014/50631-0, 2017/17471-7]
dc.description.sponsorshipBrazilian National Research Council (CNPq)/Institute for Investigation in Immunology
dc.description.sponsorshipCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil (CAPES) [001]
dc.description.sponsorshipCNPq/FAPESP
dc.identifier.citationFRONTIERS IN IMMUNOLOGY, v.10, article ID 843, 12p, 2019
dc.identifier.doi10.3389/fimmu.2019.00843
dc.identifier.issn1664-3224
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/31586
dc.language.isoeng
dc.publisherFRONTIERS MEDIA SAeng
dc.relation.ispartofFrontiers in Immunology
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright FRONTIERS MEDIA SAeng
dc.subjectHIVeng
dc.subjectmultiepitope vaccineeng
dc.subjectdendritic cell targetingeng
dc.subjectDEC205eng
dc.subjectadjuvantseng
dc.subject.otherimmunodeficiency-virus type-1eng
dc.subject.othersteady-stateeng
dc.subject.otherclonal expansioneng
dc.subject.otherreceptor dec-205eng
dc.subject.othercutting edgeeng
dc.subject.otherresponseseng
dc.subject.otheradjuvanteng
dc.subject.otherantigeneng
dc.subject.othersubsetseng
dc.subject.otherproteineng
dc.subject.wosImmunologyeng
dc.titlePoly(I:C) Potentiates T Cell Immunity to a Dendritic Cell Targeted HIV-Multiepitope Vaccineeng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.author.externalAPOSTOLICO, Juliana de Souza:Univ Fed Sao Paulo, Lab Expt Vaccines, Dept Microbiol Immunol & Parasitol, Sao Paulo, Brazil; Inst Invest Immunol Iii INCT, Sao Paulo, Brazil
hcfmusp.author.externalLUNARDELLI, Victoria Alves Santos:Univ Fed Sao Paulo, Lab Expt Vaccines, Dept Microbiol Immunol & Parasitol, Sao Paulo, Brazil; Inst Invest Immunol Iii INCT, Sao Paulo, Brazil
hcfmusp.author.externalYAMAMOTO, Marcio Massao:Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Sao Paulo, Brazil
hcfmusp.author.externalBOSCARDIN, Silvia Beatriz:Inst Invest Immunol Iii INCT, Sao Paulo, Brazil; Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Sao Paulo, Brazil
hcfmusp.author.externalROSA, Daniela Santoro:Univ Fed Sao Paulo, Lab Expt Vaccines, Dept Microbiol Immunol & Parasitol, Sao Paulo, Brazil; Inst Invest Immunol Iii INCT, Sao Paulo, Brazil
hcfmusp.citation.scopus22
hcfmusp.contributor.author-fmusphcEDECIO CUNHA NETO
hcfmusp.description.articlenumber843
hcfmusp.description.volume10
hcfmusp.origemWOS
hcfmusp.origem.pubmed31105693
hcfmusp.origem.scopus2-s2.0-85066949846
hcfmusp.origem.wosWOS:000465390400001
hcfmusp.publisher.cityLAUSANNEeng
hcfmusp.publisher.countrySWITZERLANDeng
hcfmusp.relation.referenceAkondy RS, 2009, J IMMUNOL, V183, P7919, DOI 10.4049/jimmunol.0803903eng
hcfmusp.relation.referenceAmorim KNS, 2016, SCI REP-UK, V6, DOI 10.1038/srep39250eng
hcfmusp.relation.referenceAntonialli R, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01727eng
hcfmusp.relation.referenceApostolico JD, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00101eng
hcfmusp.relation.referenceApostolico JD, 2016, J IMMUNOL RES, DOI 10.1155/2016/1459394eng
hcfmusp.relation.referenceApostolico JD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145637eng
hcfmusp.relation.referenceApostolopoulos V, 2013, J DRUG DELIV, DOI 10.1155/2013/869718eng
hcfmusp.relation.referenceBarry M, 2007, EXPERT OPIN BIOL TH, V7, P1731, DOI 10.1517/14712598.7.11.1731eng
hcfmusp.relation.referenceBaumgartner CK, 2010, IMMUNOLOGY, V130, P16, DOI 10.1111/j.1365-2567.2010.03265.xeng
hcfmusp.relation.referenceBonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598eng
hcfmusp.relation.referenceBoscardin SB, 2006, J EXP MED, V203, P599, DOI 10.1084/jem.20051639eng
hcfmusp.relation.referenceCaminschi I, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23128eng
hcfmusp.relation.referenceCheong C, 2010, BLOOD, V116, P3828, DOI 10.1182/blood-2010-06-288068eng
hcfmusp.relation.referenceCoffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002eng
hcfmusp.relation.referenceCohn L, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00255eng
hcfmusp.relation.referenceCurtsinger JM, 2005, J IMMUNOL, V174, P4465, DOI 10.4049/jimmunol.174.8.4465eng
hcfmusp.relation.referenceDhodapkar MV, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008068eng
hcfmusp.relation.referenceDudziak D, 2007, SCIENCE, V315, P107, DOI 10.1126/science.1136080eng
hcfmusp.relation.referenceEdwards AD, 2003, EUR J IMMUNOL, V33, P827, DOI 10.1002/eji.200323797eng
hcfmusp.relation.referenceFlynn BJ, 2011, P NATL ACAD SCI USA, V108, P7131, DOI 10.1073/pnas.1103869108eng
hcfmusp.relation.referenceGandhapudi SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056855eng
hcfmusp.relation.referenceGarcon N, 2017, HUM VACC IMMUNOTHER, V13, P19, DOI 10.1080/21645515.2016.1225635eng
hcfmusp.relation.referenceGaucher D, 2008, J EXP MED, V205, P3119, DOI 10.1084/jem.20082292eng
hcfmusp.relation.referenceGriffiths EA, 2018, CLIN CANCER RES, V24, P1019, DOI 10.1158/1078-0432.CCR-17-1792eng
hcfmusp.relation.referenceGuilliams M, 2016, IMMUNITY, V45, P669, DOI 10.1016/j.immuni.2016.08.015eng
hcfmusp.relation.referenceGuilliams M, 2014, NAT REV IMMUNOL, V14, P571, DOI 10.1038/nri3712eng
hcfmusp.relation.referenceGurer C, 2008, BLOOD, V112, P1231, DOI 10.1182/blood-2008-03-148072eng
hcfmusp.relation.referenceGutjahr A, 2016, TRENDS IMMUNOL, V37, P716, DOI 10.1016/j.it.2016.08.005eng
hcfmusp.relation.referenceHarari A, 2004, BLOOD, V103, P966, DOI 10.1182/blood-2003-04-1203eng
hcfmusp.relation.referenceHavenar-Daughton C, 2006, J IMMUNOL, V176, P3315, DOI 10.4049/jimmunol.176.6.3315eng
hcfmusp.relation.referenceHawiger D, 2001, J EXP MED, V194, P769, DOI 10.1084/jem.194.6.769eng
hcfmusp.relation.referenceHemmi H, 2003, J IMMUNOL, V170, P3059, DOI 10.4049/jimmunol.170.6.3059eng
hcfmusp.relation.referenceHemmi Hiroaki, 2005, V86, P120eng
hcfmusp.relation.referenceHenriques HR, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002330eng
hcfmusp.relation.referenceIdoyaga J, 2011, P NATL ACAD SCI USA, V108, P2384, DOI 10.1073/pnas.1019547108eng
hcfmusp.relation.referenceINABA K, 1995, CELL IMMUNOL, V163, P148, DOI 10.1006/cimm.1995.1109eng
hcfmusp.relation.referenceIwasaki A, 2015, NAT IMMUNOL, V16, P343, DOI 10.1038/ni.3123eng
hcfmusp.relation.referenceJoshi NS, 2007, IMMUNITY, V27, P281, DOI 10.1016/j.immuni.2007.07.010eng
hcfmusp.relation.referenceKannanganat S, 2007, J VIROL, V81, P12071, DOI 10.1128/JVI.01261-07eng
hcfmusp.relation.referenceKastenmuller W, 2014, NAT REV IMMUNOL, V14, P705, DOI 10.1038/nri3727eng
hcfmusp.relation.referenceKRAAL G, 1986, J EXP MED, V163, P981, DOI 10.1084/jem.163.4.981eng
hcfmusp.relation.referenceKwissa M, 2007, EXPERT REV VACCINES, V6, P673, DOI 10.1586/14760584.6.5.673eng
hcfmusp.relation.referenceKwissa M, 2012, BLOOD, V119, P2044, DOI 10.1182/blood-2011-10-388579eng
hcfmusp.relation.referenceLahoud MH, 2012, P NATL ACAD SCI USA, V109, P16270, DOI 10.1073/pnas.1208796109eng
hcfmusp.relation.referenceLakhrif Z, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00317eng
hcfmusp.relation.referenceLonghi MP, 2009, J EXP MED, V206, P1589, DOI 10.1084/jem.20090247eng
hcfmusp.relation.referenceLopez-Bravo M, 2008, IMMUNITY, V29, P343, DOI 10.1016/j.immuni.2008.08.008eng
hcfmusp.relation.referenceMacri C, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.6eng
hcfmusp.relation.referenceMarrack P, 1999, J EXP MED, V189, P521, DOI 10.1084/jem.189.3.521eng
hcfmusp.relation.referenceMartin M, 2003, INFECT IMMUN, V71, P2498, DOI 10.1128/IAI.71.5.2498-2507.2003eng
hcfmusp.relation.referenceMartins KA, 2015, EXPERT REV VACCINES, V14, P447, DOI 10.1586/14760584.2015.966085eng
hcfmusp.relation.referenceMata-Haro V, 2007, SCIENCE, V316, P1628, DOI 10.1126/science.1138963eng
hcfmusp.relation.referenceMcElrath MJ, 2017, CURR OPIN HIV AIDS, V12, P278, DOI 10.1097/COH.0000000000000365eng
hcfmusp.relation.referenceMcElrath MJ, 2010, IMMUNITY, V33, P542, DOI 10.1016/j.immuni.2010.09.011eng
hcfmusp.relation.referenceMerad M, 2013, ANNU REV IMMUNOL, V31, P563, DOI 10.1146/annurev-immunol-020711-074950eng
hcfmusp.relation.referenceMutwiri GK, 2004, J CONTROL RELEASE, V97, P1, DOI 10.1016/j.jcornel.2004.02.022eng
hcfmusp.relation.referencePark CG, 2014, CLIN EXP VACCINE RES, V3, P149, DOI 10.7774/cevr.2014.3.2.149eng
hcfmusp.relation.referencePrecopio ML, 2007, J EXP MED, V204, P1405, DOI 10.1084/jem.20062363eng
hcfmusp.relation.referenceRampazo EV, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117778eng
hcfmusp.relation.referenceRosa DS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016921eng
hcfmusp.relation.referenceRuane D, 2016, MUCOSAL IMMUNOL, V9, P1340, DOI 10.1038/mi.2015.133eng
hcfmusp.relation.referenceSahay B., 2017, J CLIN CELL IMMUNOL, V8, P518, DOI [10.4172/2155-9899.1000518, DOI 10.4172/2155-9899.1000518]eng
hcfmusp.relation.referenceSarkar S, 2007, J IMMUNOL, V179, P6704, DOI 10.4049/jimmunol.179.10.6704eng
hcfmusp.relation.referenceShirota H, 2017, IMMUNOPOTENTIATORS IN MODERN VACCINES, 2ND EDITION, P163, DOI 10.1016/B978-0-12-804019-5.00009-8eng
hcfmusp.relation.referenceShortman K, 2007, NAT REV IMMUNOL, V7, P19, DOI 10.1038/nri1996eng
hcfmusp.relation.referenceSilva-Sanchez A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124828eng
hcfmusp.relation.referenceSteinman RM, 2010, IMMUNOL REV, V234, P5, DOI 10.1111/j.0105-2896.2009.00888.xeng
hcfmusp.relation.referenceTeixeira D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00177eng
hcfmusp.relation.referenceTewari K, 2010, VACCINE, V28, P7256, DOI 10.1016/j.vaccine.2010.08.098eng
hcfmusp.relation.referenceThompson BS, 2005, J LEUKOCYTE BIOL, V78, P1273, DOI 10.1189/jlb.0305172eng
hcfmusp.relation.referenceTrumpfheller C, 2006, J EXP MED, V203, P607, DOI 10.1084/jem.20052005eng
hcfmusp.relation.referenceTrumpfheller C, 2012, J INTERN MED, V271, P183, DOI 10.1111/j.1365-2796.2011.02496.xeng
hcfmusp.relation.referenceTrumpfheller C, 2008, P NATL ACAD SCI USA, V105, P2574, DOI 10.1073/pnas.0711976105eng
hcfmusp.relation.referenceVilladangos JA, 2007, NAT REV IMMUNOL, V7, P543, DOI 10.1038/nri2103eng
hcfmusp.relation.referenceWang M, 2009, CLIN EXP IMMUNOL, V155, P441, DOI 10.1111/j.1365-2249.2008.03856.xeng
hcfmusp.relation.referenceWiesel M, 2012, EUR J IMMUNOL, V42, P320, DOI 10.1002/eji.201142091eng
hcfmusp.relation.referenceWiesel M, 2011, J IMMUNOL, V186, P754, DOI 10.4049/jimmunol.1003166eng
hcfmusp.relation.referenceWilson NA, 2009, J VIROL, V83, P6508, DOI 10.1128/JVI.00272-09eng
hcfmusp.relation.reference2010, EUR J IMMUNOL, V40, P2791, DOI 10.1002/EJI.201040511eng
hcfmusp.relation.reference2004, J EXP MED, V199, P815, DOI 10.1084/JEM.20032220eng
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublicationa2838f87-56ea-4579-a377-387e8fed37e5
relation.isAuthorOfPublication.latestForDiscoverya2838f87-56ea-4579-a377-387e8fed37e5
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_APOSTOLICO_PolyIC_Potentiates_T_Cell_Immunity_to_a_Dendritic_2019.PDF
Tamanho:
4.27 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/19
Artigos e Materiais de Revistas Científicas - ODS/03